丁基-4抑制剂使用者与非使用者之间预后的比较
Hideaki Hashimoto1,2,3, Michihiro Satoh2,3,4, Shingo Nakayama1,2
1Division of Nephrology and Endocrinology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Diabetes, obesity & metabolism
|August 1, 2024
概括
与非使用者相比,二乙酶-4抑制剂 (DPP-4i) 用户在亚洲的一项真实研究中表现出更好的功能和较低的末期病风险. 这些发现表明DPP-4抑制剂可能提供保护性益处.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病管理通常涉及影响功能的药物.
- 双基化酶-4抑制剂 (DPP-4i) 是常用的抗糖尿病药物.
- 亚洲人群中DPP-4i使用者的预后的现实数据有限.
研究的目的:
- 为了比较二二二酶-4抑制剂 (DPP-4i) 用户和非使用者之间的预后.
- 评估DPP-4i对估计的膜过率 (eGFR) 降低和末期病 (ESKD) 发展的影响.
- 利用现实世界中的亚洲数据进行可靠的分析.
主要方法:
- 2014-2021年30岁以上的抗糖尿病药物使用者的回顾性分析.
- 倾向性得分匹配比较DPP-4i用户和非用户.
- 主要结局:eGFR下降 (eGFR≥45毫升/分钟/1.73米2) 和ESKD发展 (eGFR<45毫升/分钟/1.73米2).
主要成果:
- 在EGFR≥45组中,DPP-4i使用者在2年和3年后的EGFR下降显著减慢.
- 在eGFR < 45组中,DPP-4i用户的ESKD发病率显著降低 (1.15%对2.30%).
- 倾向性得分匹配创造了16002对 (eGFR ≥45) 和2086对 (eGFR <45).
结论:
- 与非使用者相比,使用二乙酶-4抑制剂 (DPP-4i) 的患者表现出更好的预后.
- 在这个真实世界的亚洲队列中,DPP-4i使用与更慢的eGFR衰退和ESKD风险降低有关.
- 这些发现支持DPP-4抑制剂在糖尿病患者中具有潜在的保护作用.
更多相关视频
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
Renal Failure: Dose Adjustments
77
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
77
Glucagon-like Receptor Agonists
312
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
312
Factors Affecting Renal Clearance: Renal Impairment
69
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
69
Insulin: Dosing Regimen and Adverse Effects
163
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
163
Renal Drug Clearance: Comparison Between Renal Excretion Methods
108
Renal clearance is a critical parameter encompassing kidney filtration, secretion, and reabsorption processes. It is calculated using a specific equation to determine the rate at which the kidneys clear a drug.
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
108


